“We are very pleased with the study results obtained so far, which are far better than we dared to hope for. These strengthen the image of ODX as a candidate for the treatment of treatment-resistant multiple myeloma, and also without significant side effects,” says CEO Anders R Holmberg.

The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex (ODX) are studied, 3mg/kg body weight, 6mg/kg, and 9mg/kg. Adult myeloma patients with progressive treatment-resistant disease, who have previously received 1–5 prior lines of therapy, are included in the study. The primary objective is to confirm ODX safety and tolerability and with a secondary objective to demonstrate indications of treatment response.

The last patient in dose group 2 (6mg/kg) was finished in week 50 (7 doses) and has had his last visit. The patient then continued to have stable disease. All patients in dose group 3 (9mg/kg) have achieved stable disease and will be completed by the end of February. No significant ODX related side effects have been noted. Patients with stable disease after completion of ODX treatment are followed until new progress to map how long the disease-inhibiting effect persists. Data obtained so far show that the disease-inhibiting effect in some cases persists for months and at most up to six months without initiation of other cancer treatment.